Achillion Announces Upcoming Oral Presentation and Nomination of ACH-4471 at #ASH2015

Achillion Pharmaceuticals, Inc. ACHN announced Saturday, that an upcoming oral presentation discussing the Company's novel small molecule factor D inhibitors will take place on Sunday, December 6, 2015 during the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL, December 5 – 8. Achillion also announced today the nomination of its first orally bioavailable, highly potent and specific factor D inhibitor, ACH-4471, which is expected to enter clinical development during the first quarter of 2016. "We believe our molecular level understanding of factor D has enabled us to develop exquisitely targeted inhibitors that can potentially provide highly See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsManagementPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!